Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T-cell) therapies that have demonstrated significant efficacy in patients with heavily pretreated MM patients, as shown in the pivotal KarMMa-1 and CARTITUDE-1 trials, respectively (10, 11). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.